Back to Search
Start Over
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies
- Publication Year :
- 2021
- Publisher :
- Elsevier Ireland Ltd, 2021.
-
Abstract
- The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the regulatory issues, ultimately granting the possibility of translating this model in the "real world". In this position paper, based on experts' opinion, the AIOM-SIAPEC-IAP-SIBIOC-SIF Italian Scientific Societies revised the new agnostic biomarkers, the diagnostic technologies available, the current availability of agnostic drugs and their present indication.
- Subjects :
- Societies, Scientific
Genomic profiling
Druggability
NTRK-Fusions
Medical Oncology
Neoplasms
Medicine
Humans
Agnostic biomarkers
Precision Medicine
Histology-agnostic
Tumor histology
business.industry
Agnostic drugs
Homologous recombination deficiency
Microsatellite instability
Mismatch repair deficiency
Precision oncology
Italy
Scientific
Hematology
Precision medicine
Data science
Oncology
Economic sustainability
Agnostic biomarker
Position paper
Neoplasm
Identification (biology)
Personalized medicine
Agnostic drug
NTRK-Fusion
business
Societies
Human
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....577fbce50a2c513b1a2791ddcb791986